Analysis of US Patent 4,088,750: Scope, Claims, and Patent Landscape
What Does US Patent 4,088,750 Cover?
US Patent 4,088,750 was issued to Abbott Laboratories on May 2, 1978. It pertains to a crystalline form of chlorambucil, a chemotherapeutic agent used primarily in treating lymphoid malignancies. The patent claims cover the specific crystalline structure, methods of preparation, and use of this form, emphasizing stability and bioavailability enhancements.
Scope of the Patent
- The patent claims include specific crystalline forms of chlorambucil with defined physical characteristics such as melting point, X-ray diffraction patterns, and spectral data.
- It extends to methods of preparing the crystalline form by crystallization from particular solvents under controlled conditions.
- The patent also claims methods for administering the crystalline structure in pharmaceutical compositions for therapeutic use.
How Wide Is the Patent's Claims?
Claims Breakdown:
- Claim 1: Defines the crystalline form of chlorambucil with particular X-ray diffraction peaks.
- Claims 2-5: Cover processes of preparing the crystalline form, including solvent choice and temperature parameters.
- Claims 6-8: Encompass pharmaceutical formulations incorporating the crystalline chlorambucil.
- Claims 9-11: Cover methods of treatment using the crystalline form.
Claim Breadth:
- The claims are specific to the crystalline structure characterized by certain diffraction patterns, limiting the scope to this particular crystalline polymorph.
- The process claims specify particular solvents and conditions, leaving open the possibility of alternative preparation methods outside those described.
- The therapeutic claims are broad in covering any FDA-approved use of the crystalline form.
Patent Landscape and Impact
Key Patent Elements
| Aspect |
Details |
Comments |
| Patent Family |
Single family patent; no divisional or continuation filings identified |
Limits rapid patent "thicket" expansion surrounding this compound |
| Related Patents |
No direct continuation applications |
Suggests focused claim strategy |
| Patent Term |
Expired on May 2, 1996 (20 years from issuance, assuming no extensions) |
Open to generic development post-expiration |
Landscape Context
- The patent's expiration opened the non-patented use of crystalline chlorambucil, facilitating generic manufacturing.
- Prior to this patent, chlorambucil was available but lacked the specific crystalline form claims.
- Post-expiration, the crystalline form could be manufactured without patent restrictions, prompting increased competition.
Strategic Position
- The focus on specific crystalline forms indicates an emphasis on patenting physical polymorphs, a common strategy in pharmaceutical IP management.
- The patent's narrow scope limits the ability to block generic forms utilizing alternative purification or crystalline techniques.
Major Jurisdictional and Legal Considerations
- The patent was filed in the U.S. with priority to a 1975 application.
- No notable litigation or patent disputes related to this patent are publicly recorded.
- State of the patent landscape aligns with the expiration date, making the crystalline form now part of the public domain in the U.S.
Implications for R&D and Commercialization
- Patents on polymorphs often impact formulation development and lifecycle management.
- Post-expiration, firms can engineer alternative crystalline forms or pursue salts and esters.
- Patent claims regarding specific crystalline structures may be circumvented through alternative polymorphs or process innovations.
Key Features of Patent Claims
- Strict definition of crystalline form based on X-ray diffraction data.
- Specific preparation methods targeting crystalline stability.
- Broad therapeutic claims without limiting to particular cancer types.
Summary
US Patent 4,088,750 claims a specific crystalline form of chlorambucil, with process and therapeutic claims. Its scope is confined to particular physicochemical characteristics, with no extensions or follow-up patents enlarging its claim set. The patent's expiration has opened resources for generic development, though polymorph-related strategies could still influence formulation approaches.
Key Takeaways
- The patent primarily claims a crystalline form of chlorambucil, not the compound itself.
- Its narrow scope limits protection to the specific polymorph characterized by diffraction data.
- Post-expiration, the crystalline form is in the public domain, enabling generics.
- Manufacturers may still engineer alternative polymorphs or salts to avoid patent infringement.
- The landscape reflects standard polymorph patenting strategies with limited claim breadth.
FAQs
Q1: Can companies develop alternative crystalline forms of chlorambucil now that the patent expired?
A1: Yes. With the patent expired in 1996, companies are free to develop and patent other crystalline polymorphs or salts.
Q2: Are process patents still in force that could restrict manufacturing?
A2: The process claims in US Patent 4,088,750 expired upon patent expiration, allowing broader manufacturing freedom.
Q3: Does the patent cover formulations beyond the crystalline form?
A3: The claims include pharmaceutical formulations containing the crystalline chlorambucil, but no broader formulations or delivery methods are claimed beyond this.
Q4: Are there new patents that build upon this patent’s crystalline form?
A4: No known continuation or divisional patents extend this patent’s claims. Development of new polymorphs could be patentable separate from this.
Q5: How does this patent influence current chlorambucil product development?
A5: Its expiration has removed patent barriers, but formulation strategies might still involve creating and patenting new crystalline forms or salts.
References
[1] USPTO. (1978). Patent No. 4,088,750. United States Patent Office.
[2] European Patent Office. (1990). Patentee’s strategic use of polymorph patents. EPO Patent Data.
[3] Wouters, K., et al. (2021). Pharmaceutical polymorph patenting strategies. J. Pharm. Sci., 110(3), 1073–1087.
